Use of a biochip for the diagnosis of sepsis or sepsis related syndrome

• US 20040259090A1
• Filed: 07/28/2004
• Published: 12/23/2004
• Est. Priority Date: 06/29/2001
• Status: Abandoned Application

• Current Assignee: SIRS-Lab GmbH (Noblex GmbH)
• Original Assignee: SIRS-Lab GmbH (Noblex GmbH)
• Inventors: Russwurm, Stefan, Saluz, Hans-Peter, Reinhart, Konrad, Zipfel, Peter Franz
• Application Number:
  US10/482,353
• Publication Number:
  US 20040259090A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence

Abstract

The application relates to the use of a nucleic acid and/or protein chip comprising probe nucleic acids and/or probe proteins, which are specific for cellular stress, inflammatory and immune reactions, associated with stress, inflammatory and immune reactions, induced during acute phase responses or any combination thereof and which are immobilised on a carrier for the diagnosis of sepsis or sepsis related syndrome.

Claims

1. A method of detecting a condition of sepsis or sepsis related syndrome, the method comprising:

providing a chip that comprises a plurality of nucleic acid probes immobilized to the chip, wherein each of the nucleic acid probes in the plurality of nucleic acid probes are hybridizable to at least a fragment of a gene and the gene encodes a molecule associated with a body response to sepsis or infection.

2. The method of claim 1 wherein the gene is a member of the group consisting of immune mediators, transcription factors, acute phase proteins, complement components, adhesion molecules, apoptosis, housekeeping genes, markers for cell specificity, molecules of the coagulation system, and genes in an infectious agent.

3. The method of claim 1 wherein the gene is a splice variant of a gene.

4. The method of claim 1 wherein the gene is a member of the group consisting of immune mediators, transcription factors, acute phase proteins, complement components, adhesion molecules, apoptosis, housekeeping genes, and markers for cell specificity.

5. The method of claim 1 wherein the probes are immobilized to the chip in predetermined areas.

6. The method of claim 5 wherein the areas are separated from each other.

7. The method of claim 1 wherein the chip comprises a glass slide, a microtiter plate, or a nanotiter plate.

8. The method of claim 1 further comprising exposing the probes on the chip to a sample, wherein the sample comprises labeled mRNA or labeled cDNA.

9. The method of claim 8 wherein the labeled mRNA or labeled cDNA is used to quantitatively measure a concentration of mRNA, cDNA, or both mRNA and cDNA in the sample.

10. The method of claim 1 comprising examining the chip after the chip is exposed to a sample taken from the body to determine if sepsis or sepsis related syndrome is indicated in the body.

11. An assay system for diagnosis of sepsis or sepsis related syndrome in a body, wherein the assay system comprises a chip and a plurality of nucleic acid probes immobilized to the chip, wherein each of the nucleic acid probes in the plurality of nucleic acid probes are hybridizable to at least a fragment of a gene, and the gene encodes a molecule associated with a body response to sepsis or infection, wherein hybridization of the plurality of probes provides an indication concerning sepsis or sepsis related syndrome.

12. The assay system of claim 11 wherein the gene is a member of the group consisting of immune mediators, transcription factors, acute phase proteins, complement components, adhesion molecules, apoptosis, housekeeping genes, markers for cell specificity, molecules of the coagulation system, and genes in an infectious agent.

13. The assay system of claim 11 wherein the fragment of the gene is a splice variant of a gene.

14. The assay system of claim 11 wherein the gene is a member of the group consisting of immune mediators, transcription factors, acute phase proteins, complement components, adhesion molecules, apoptosis, housekeeping genes, and markers for cell specificity.

15. The assay system of claim 11 wherein the probes are immobilized to the chip in predetermined areas.

16. The assay system of claim 15 wherein the areas are separated from each other.

17. The assay system of claim 11 wherein the chip comprises a glass slide, a microtiter plate, or a nanotiter plate.

18. The assay system of claim 11 further comprising labeled mRNA or labeled cDNA hybridizable to probes on the chip.

19. The assay system of claim 18 wherein the labeled mRNA or labeled cDNA is used to quantitatively measure a concentration of mRNA, cDNA, or both mRNA and cDNA in a sample that is exposed to the chip.

20. The assay system of claim 11 comprising a sample taken from the body to determine if sepsis or sepsis related syndrome is indicated in the body after the chip is exposed to the sample.